AKLIEF- trifarotene cream
Galderma Laboratories, L.P.

trifarotene chemical structure45-gram-carton-image


AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.


Apply a thin layer of AKLIEF Cream to the affected areas once daily, in the evening, on clean and dry skin.

  • One pump actuation should be enough to cover the face (i.e., forehead, cheeks, nose, and chin).
  • Two actuations of the pump should be enough to cover the upper trunk (i.e., reachable upper back, shoulders and chest). One additional pump actuation may be used for middle and lower back if acne is present.

The use of a moisturizer is recommended as frequently as needed from the initiation of treatment.
Avoid contact with the eyes, lips, paranasal creases, mucous membranes.
AKLIEF Cream is for topical use only. Not for oral, ophthalmic, or intravaginal use.


Cream: 0.005%. Each gram of AKLIEF Cream contains 50 mcg of trifarotene in a white cream.




5.1 Skin Irritation

Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Maximum severity of these reactions typically occurred within the first 4 weeks of treatment, and severity decreased with continued use of the medication. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of application of AKLIEF Cream, or suspend use temporarily. If severe reactions persist the treatment may be discontinued.
Avoid application of AKLIEF Cream to cuts, abrasions, or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream.

5.2 Ultraviolet Light and Environmental Exposure

Minimize unprotected exposure to ultraviolet rays (including sunlight and sunlamps) during treatment with AKLIEF Cream. Warn patients who normally experience high levels of sun exposure and those with inherent sensitivity to sun to exercise caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided.


6.1 Clinical trials experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect rates observed in practice. In the three Phase 3 clinical trials, 1673 subjects with acne vulgaris on the face and trunk, 9 years and older were exposed to AKLIEF Cream. Of these, 1220 subjects were treated once daily for up to 12 weeks and 453 were treated once daily for up to 1 year.
Adverse reactions reported in the 2 randomized, double-blind, vehicle-controlled 12-week clinical trials in 1.0% of subjects treated with AKLIEF Cream (and for which the rate exceeded the rate for vehicle), as well as the corresponding rates reported in subjects treated with the vehicle cream are presented in Table 1.

Table 1. Adverse Reactions Occurring in ≥ 1.0% of Subjects with Acne Vulgaris of the Face and Trunk in the Two 12-week Phase 3 Clinical Trials
Preferred Term AKLIEF Cream(N=1220) VehicleCream(N=1200)
Application site irritation 91 (7.5) 4 (0.3)
Application site pruritus 29 (2.4) 10 (0.8)
Sunburn 32 (2.6) 6 (0.5)

Additional adverse reactions that were reported in more than one subject treated with AKLIEF Cream (and at a frequency <1%) included application site pain, application site dryness, application site discoloration, application site rash, application site swelling, application site erosion, acne, dermatitis allergic, and erythema.
In the one-year, open-label safety trial that included 453 subjects 9 years and older, with acne vulgaris of the face and trunk, the pattern of adverse reactions for AKLIEF Cream was similar to that experienced in the 12-week controlled trials. A total of 12.6% of subjects had at least one adverse reaction during the trial, and 2.9% of subjects had an adverse reaction leading to treatment discontinuation. The most common adverse reactions (≥1% of subjects) for the entire trial were application site pruritus (4.6%), application site irritation (4.2%), and sunburn (5.5%). The frequency of adverse reactions decreased over time.
Skin irritation was evaluated by active assessment of erythema, scaling, dryness, and stinging/burning and collected separately. In the two 12-week Phase 3 clinical trials, these signs/symptoms were assessed at baseline and at least one post-baseline visit, in 1214 subjects (for face) and 1202 subjects (for trunk) treated with AKLIEF Cream. The percentage of subjects who were assessed to have these signs and symptoms at any post baseline visit and at a severity worse than baseline are summarized in Table 2.

Table 2. Application Site Tolerability Reactions at Any Post Baseline Visit
Face AKLIEF CreamN=1214Maximum Severity during Treatment Vehicle CreamN=1194Maximum Severity during Treatment
Mild Moderate Severe Mild Moderate Severe
Erythema 30.6% 28.4% 6.2% 21% 6.8% 0.8%
Scaling 37.5% 27.1% 4.9% 23.7% 5.9% 0.3%
Dryness 39% 29.7% 4.8% 29.9% 6.8% 0.8%
Stinging/Burning 35.6% 20.6% 5.9% 15.9% 3.8% 0.5%
Trunk N=1202 N=1185
Erythema 26.5% 18.9% 5.2% 12.7% 4.4% 0.4%
Scaling 29.7% 13.7% 1.7% 13.2% 2.6% 0.1%
Dryness 32.9% 16.1% 1.8% 17.8% 3.9% 0.1%
Stinging/Burning 26.1% 10.9% 4.3% 9.2% 2.2% 0.5%

Local tolerability on the face in subjects treated with AKLIEF Cream worsened for any of the signs/symptoms compared with baseline to a score of moderate for up to 30% of subjects, or severe for up to 6% of subjects. On the trunk, the corresponding percentages were up to 19% (moderate) and up to 5% (severe). The scores reached maximum severity at Week 1 for the face, and at Week 2 to 4 of treatment for the trunk, and decreased thereafter.
In the open-label, 1-year Phase 3 trial, the local tolerability profile was comparable to that observed in the two pivotal Phase 3 trials.

Page 1 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.